MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.850
-0.020
-1.07%
Closed 19:38 07/14 EDT
OPEN
1.870
PREV CLOSE
1.870
HIGH
1.900
LOW
1.800
VOLUME
333.53K
TURNOVER
--
52 WEEK HIGH
8.76
52 WEEK LOW
1.350
MARKET CAP
60.75M
P/E (TTM)
-1.1030
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SYBX stock price target is 7.25 with a high estimate of 13.00 and a low estimate of 2.000.

EPS

SYBX News

More
Edited Transcript of SYBX.OQ earnings conference call or presentation 8-May-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/18 02:38
Is Synlogic, Inc. (SYBX) A Good Stock To Buy?
Insider Monkey · 06/12 16:19
IPO Update: Generation Bio Proposes IPO Terms
Seeking Alpha - Article · 06/09 19:31
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors
PR Newswire · 06/01 10:46
Synlogic Hosts First Virtual R&D Event
PR Newswire · 05/27 13:00
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/22 09:26
Synlogic to Host Virtual R&D Event
PR Newswire · 05/21 21:02
51 Stocks Moving In Thursday's Mid-Day Session
Gainers Seneca Biopharma, Inc. (NASDAQ: SNCA) jumped 99% to $1.6350.
Benzinga · 05/21 17:18

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About SYBX

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
More

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.